Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib und dexamethasone) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A21-60
Last updated

Report documents

  1. Extract of dossier assessment

    Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib und dexamethasone) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 786 kB, EN, not accessible
    Download file : Extract of dossier assessment (PDF document, 786 kB, EN, not accessible)

  2. Dossier assessment

    Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib und dexamethasone) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
    Download file : Dossier assessment (PDF document, 1 MB, DE, not accessible)

Dossier assessment

Indication:

Adults with multiple myeloma who have received at least one prior therapy

Result of dossier assessment:

Added benefit not proven.

Additional information

Federal Joint Committee (G-BA)
2021-11-04 A G-BA decision was published.
G-BA documents on this decision

Project details

Project no.
A21-60
Commission
Commission awarded on 12.05.2021 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Isatuximab (multiple myeloma after >= 2 prior therapies, combination with pomalidomide und dexamethasone) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-61
    Last updated

    Status: Commission completed

  2. Addendum

    Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib and dexamethasone) - Addendum to Commission A21-60

    Project no.
    A21-123
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Isatuximab (newly diagnosed multiple myeloma, eligible for stem cell transplant) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-105
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Isatuximab (multiple myeloma, first line, combination with bortezomib, lenalidomide and dexamethasone) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-20
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page